May 25, 2017 1:29 AM ET


Company Overview of Infinity Pharmaceuticals, Inc.

Company Overview

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; In...

784 Memorial Drive

Cambridge, MA 02139

United States

56 Employees





Key Executives for Infinity Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 56
Total Annual Compensation: $668.8K
President, Principal Accounting Officer and Treasurer
Age: 50
Total Annual Compensation: $417.7K
Vice President, General Counsel and Secretary
Age: 37
Total Annual Compensation: $265.8K
Compensation as of Fiscal Year 2016.

Infinity Pharmaceuticals, Inc. Key Developments

Infinity Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Earnings Guidance for the Full Year 2017; Provides Update on IPI-549 Dose-Escalation in Phase 1 Clinical Study

Infinity Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company's loss from operations was $10,476,000 against $40,768,000 a year ago. Net loss was $10,475,000 or $0.21 per basic and diluted share against $40,664,000 or $0.82 per basic and diluted share a year ago. The company expects net loss for 2017 to range from $40 million to $50 million. The company provided an update on the company, including its progress with IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Infinity is evaluating IPI-549 as a monotherapy and in combination with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, in a Phase 1 study in patients with advanced solid tumors. Dose-escalation data from the ongoing study were presented in April at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. These data demonstrated that IPI-549 was well tolerated both as a monotherapy and in combination with Opdivo. Additionally, data from the monotherapy module of the study showed IPI-549 has a favorable pharmacokinetic (PK) and pharmacodynamic (PD) profile that supports once daily (QD) dosing. IPI-549 is believed to be the only selective PI3K-gamma inhibitor in clinical development. IPI-549 has a number of key attributes that have enabled to rapidly enroll patients in ongoing study. It is orally administered, is believed to be the only selective PI3K-gamma inhibitor in clinical development, and has demonstrated a favorable tolerability profile, both as a monotherapy as well as in combination with Opdivo, stated Adelene Perkins, Infinity's chair and chief executive officer. Additionally, there is a strong body of preclinical translational research supporting the program demonstrating that selectively targeting PI3K-gamma with IPI-549 reprograms macrophages from a pro-tumor to an anti-tumor phenotype and is able to help overcome resistance to checkpoint inhibition, representing a unique and potentially transformative approach within immuno-oncology. The company's dose-escalation phases evaluating IPI-549 alone and with Opdivo are ongoing, and the company is on track to initiate the expansion phases in the second half of the year. The expansion phases will allow to generate additional clinical data from monotherapy treatment as well as from the combination of IPI-549 and Opdivo in specific types of solid tumors. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, activity, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy and in combination with Opdivo in approximately 175 patients with advanced solid tumors. The study includes four phases, or modules: monotherapy dose escalation, combination therapy dose escalation, monotherapy expansion, and combination therapy expansion. The combination expansion module will include multiple cohorts designed to evaluate IPI-549 in patients with specific types of cancer, including patients with non-small cell lung cancer (NSCLC), melanoma, and squamous cell carcinoma of the head and neck (SCCHN) whose tumors show initial resistance or subsequently develop resistance to immune checkpoint blockade therapy. There is a great need for additional treatment options for the growing number of patients living with these cancers, which account for more than 17% of all new cancer cases in the U.S.

Infinity Pharmaceuticals, Inc., Q1 2017 Earnings Call, May 09, 2017

Infinity Pharmaceuticals, Inc., Q1 2017 Earnings Call, May 09, 2017

Infinity Pharmaceuticals, Inc. Announces Management Changes

On April 5, 2017, José Baselga, M.D., Ph.D., informed Infinity Pharmaceuticals, Inc. of his decision to retire from Board of Directors effective at the end of his current term, which expires on the date of 2017 Annual Meeting of Stockholders (the ‘Annual Meeting’). Accordingly, Dr. Baselga will not stand for re-election to Board at 2017 Annual Meeting. On April 5, 2017, the company’s Board, based on the recommendation of the Nominating and Governance Committee of Board (the ‘Governance Committee’), elected Michael G. Kauffman, M.D., Ph.D., as an independent director. Additionally, the company’s Board, based on the recommendation of the Governance Committee, appointed Dr. Kauffman to the Governance Committee and the Research and Development Committee of Board. His term began on April 5, 2017, and will expire at 2017 annual meeting of stockholders or his earlier death, resignation, or removal.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

November 3, 2016
Infinity Pharmaceuticals Inc., Worldwide License To PI3K-Delta and PI3K-Gamma

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Infinity Pharmaceuticals, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at